“There were questionable ties between Medtronic and physician consultants who tested and reviewed the company's product, the U.S. Senate Finance Committee said in the report, which concludes a 16-month investigation covering 5,000 documents relating to 13 studies of Infuse.
“Medtronic paid about $210 million in royalties and consulting fees to the authors of company-sponsored studies between November 1996 and December 2010, the report said.
“Those sponsored studies failed to mention complications from the product, including male sterility, an increased risk of cancer, infections, bone dissolution and worsened back and leg pain.”
The Medtronic Infuse bone graft was approved by the Food and Drug Administration as a sanctioned medical device designed to stimulate spinal bone growth in patients suffering from lower spine degenerative diseases.
Resource4thePeople said that its lawyers are investigating claims from patients who are complaining about such serious health problems as severe back and leg pain, infections, bone deterioration, sterility and cancer.
These cases primarily involve situations in which the Infuse was used in what is called an off-label use, such as to the neck area. Victims of these side effects will be informed about the possibility of compensation for pain and suffering, loss of wages, medical costs and other expenses associated with the surgeries.
“Resource4thePeople is shocked by the findings of the Senate Finance Committee which, in very strongly worded language, said that Medtronic essentially attempted to sway public opinion about the safety of their product by paying millions of dollars to doctors and researchers to write positive reviews,” the organization said in announcing the legal referrals.
“When a bipartisan committee issues such a report it obviously shows the strong feelings that our elected officials have
Copyright©2012 Vocus, Inc.
All rights reserved